123 related articles for article (PubMed ID: 9452319)
1. Quantitative study of mitochondrial complex I in platelets of parkinsonian patients.
Blandini F; Nappi G; Greenamyre JT
Mov Disord; 1998 Jan; 13(1):11-5. PubMed ID: 9452319
[TBL] [Abstract][Full Text] [Related]
2. Assay of [3H]dihydrorotenone binding to complex I in intact human platelets.
Blandini F; Greenamyre JT
Anal Biochem; 1995 Sep; 230(1):16-9. PubMed ID: 8585613
[TBL] [Abstract][Full Text] [Related]
3. [3H]dihydrorotenone binding to NADH: ubiquinone reductase (complex I) of the electron transport chain: an autoradiographic study.
Higgins DS; Greenamyre JT
J Neurosci; 1996 Jun; 16(12):3807-16. PubMed ID: 8656275
[TBL] [Abstract][Full Text] [Related]
4. Intrastriatal neurotoxin injections reduce in vitro and in vivo binding of radiolabeled rotenoids to mitochondrial complex I.
Kilbourn MR; Charalambous A; Frey KA; Sherman P; Higgins DS; Greenamyre JT
J Cereb Blood Flow Metab; 1997 Mar; 17(3):265-72. PubMed ID: 9119899
[TBL] [Abstract][Full Text] [Related]
5. Mitochondrial complex I and II activities of lymphocytes and platelets in Parkinson's disease.
Yoshino H; Nakagawa-Hattori Y; Kondo T; Mizuno Y
J Neural Transm Park Dis Dement Sect; 1992; 4(1):27-34. PubMed ID: 1347219
[TBL] [Abstract][Full Text] [Related]
6. In vivo labeling of mitochondrial complex I (NADH:ubiquinone oxidoreductase) in rat brain using [(3)H]dihydrorotenone.
Talpade DJ; Greene JG; Higgins DS; Greenamyre JT
J Neurochem; 2000 Dec; 75(6):2611-21. PubMed ID: 11080215
[TBL] [Abstract][Full Text] [Related]
7. Evidence that the blockade of mitochondrial respiration by the neurotoxin 1-methyl-4-phenylpyridinium (MPP+) involves binding at the same site as the respiratory inhibitor, rotenone.
Krueger MJ; Singer TP; Casida JE; Ramsay RR
Biochem Biophys Res Commun; 1990 May; 169(1):123-8. PubMed ID: 2350337
[TBL] [Abstract][Full Text] [Related]
8. Interaction of 1-methyl-4-phenylpyridinium ion (MPP+) and its analogs with the rotenone/piericidin binding site of NADH dehydrogenase.
Ramsay RR; Krueger MJ; Youngster SK; Gluck MR; Casida JE; Singer TP
J Neurochem; 1991 Apr; 56(4):1184-90. PubMed ID: 2002336
[TBL] [Abstract][Full Text] [Related]
9. Reduced NADH coenzyme Q dehydrogenase activity in platelets of Parkinson's disease, but not Parkinson plus patients, from an Indian population.
Varghese M; Pandey M; Samanta A; Gangopadhyay PK; Mohanakumar KP
J Neurol Sci; 2009 Apr; 279(1-2):39-42. PubMed ID: 19176229
[TBL] [Abstract][Full Text] [Related]
10. Paraquat neurotoxicity is distinct from that of MPTP and rotenone.
Richardson JR; Quan Y; Sherer TB; Greenamyre JT; Miller GW
Toxicol Sci; 2005 Nov; 88(1):193-201. PubMed ID: 16141438
[TBL] [Abstract][Full Text] [Related]
11. Complex I and Parkinson's disease.
Greenamyre JT; Sherer TB; Betarbet R; Panov AV
IUBMB Life; 2001; 52(3-5):135-41. PubMed ID: 11798025
[TBL] [Abstract][Full Text] [Related]
12. Complex I inhibitors induce dose-dependent apoptosis in PC12 cells: relevance to Parkinson's disease.
Hartley A; Stone JM; Heron C; Cooper JM; Schapira AH
J Neurochem; 1994 Nov; 63(5):1987-90. PubMed ID: 7931358
[TBL] [Abstract][Full Text] [Related]
13. The content of intracellular mitochondrial DNA is decreased by 1-methyl-4-phenylpyridinium ion (MPP+).
Miyako K; Kai Y; Irie T; Takeshige K; Kang D
J Biol Chem; 1997 Apr; 272(15):9605-8. PubMed ID: 9092484
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of platelet aggregation by 1-methyl-4-phenyl pyridinium ion (MPP+) through ATP depletion: Evidence for the reduced platelet activities in Parkinson's disease.
Lim KM; Kim HH; Bae ON; Noh JY; Kim KY; Kim SH; Chung SM; Shin S; Kim HY; Chung JH
Platelets; 2009 May; 20(3):163-70. PubMed ID: 19437333
[TBL] [Abstract][Full Text] [Related]
15. Dysfunction of mitochondrial complex I and the proteasome: interactions between two biochemical deficits in a cellular model of Parkinson's disease.
Höglinger GU; Carrard G; Michel PP; Medja F; Lombès A; Ruberg M; Friguet B; Hirsch EC
J Neurochem; 2003 Sep; 86(5):1297-307. PubMed ID: 12911637
[TBL] [Abstract][Full Text] [Related]
16. Platelet mitochondrial activity and pesticide exposure in early Parkinson's disease.
Bronstein JM; Paul K; Yang L; Haas RH; Shults CW; Le T; Ritz B
Mov Disord; 2015 May; 30(6):862-6. PubMed ID: 25757798
[TBL] [Abstract][Full Text] [Related]
17. Altered redox state of platelet coenzyme Q10 in Parkinson's disease.
Götz ME; Gerstner A; Harth R; Dirr A; Janetzky B; Kuhn W; Riederer P; Gerlach M
J Neural Transm (Vienna); 2000; 107(1):41-8. PubMed ID: 10809402
[TBL] [Abstract][Full Text] [Related]
18. Novel mitochondrial DNA mutations in Parkinson's disease.
Richter G; Sonnenschein A; Grünewald T; Reichmann H; Janetzky B
J Neural Transm (Vienna); 2002 May; 109(5-6):721-9. PubMed ID: 12111463
[TBL] [Abstract][Full Text] [Related]
19. Evidence that the inhibition sites of the neurotoxic amine 1-methyl-4-phenylpyridinium (MPP+) and of the respiratory chain inhibitor piericidin A are the same.
Ramsay RR; Krueger MJ; Youngster SK; Singer TP
Biochem J; 1991 Jan; 273(Pt 2)(Pt 2):481-4. PubMed ID: 1991043
[TBL] [Abstract][Full Text] [Related]
20. Mitochondrial function in Parkinson's disease cybrids containing an nt2 neuron-like nuclear background.
Esteves AR; Domingues AF; Ferreira IL; Januário C; Swerdlow RH; Oliveira CR; Cardoso SM
Mitochondrion; 2008 Jun; 8(3):219-28. PubMed ID: 18495557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
